Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits
about
Conceptual framework for outcomes research studies of hepatitis C: an analytical reviewMedical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit.The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus.Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in EgyptRetrospective analysis of hepatitis C infected patients treated through an integrated care model.Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review.Beclabuvir for the treatment of hepatitis C.Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome.Buying cures versus renting health: Financing health care with consumer loans.Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy.The impact of hepatitis C virus outside the liver: Evidence from Asia.The impact of antiviral therapy for hepatitis C on the quality of life: a perspective.Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model.Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response.Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis.Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients.Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy.Impact of hepatitis C oral therapy in portal hypertension.Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.Editorial: hepatitis C virus (HCV) disease progression - HCV cure and the elimination of the "ethnic slope".The new hepatitis C virus bottleneck: Can delaying therapy be justified?Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015.Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study.[Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy].Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians.Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia
P2860
Q26745582-50204301-FFD2-47A8-8642-5BD4F421CCF7Q33853664-B479CE74-7BB4-4C49-81DB-F68F2BDB8FA6Q35958590-48603B43-1270-4D5D-BC8E-6DA1F1D4BF54Q36110868-458CE90D-AF2A-4718-8D3D-C123A50D9F63Q36256411-C910CA00-4EDB-4CAD-928B-B4905A5D88E5Q37338952-CE674AD2-5CF6-43DF-B58C-0940EEE20E80Q37610878-0D71F1CB-F93D-4ABE-82F3-219F529296E6Q38544196-8203BE3A-C51D-4F31-BEE2-B4D7315C31E9Q38663336-854D7E29-E031-4B74-9237-06587EB99AC8Q38749220-0AC13F8B-F482-457A-86DB-736AE664E7A8Q38947814-BC36DFC7-F598-4082-9454-F0C073D165C4Q38982462-9CB17F07-AA6E-420F-8FD0-0F4873B0B831Q39067380-497C6769-81F7-4BC4-BB00-8160E0F5B004Q40050887-D1078FB0-744D-4ED8-B76C-7E10CCD6DB32Q40098372-DA8ACC00-A0A8-4574-AC21-561F421D5BAFQ40302226-60A327DA-073D-42AB-B6B5-B75BE87422F9Q40582320-F70CB417-FDD2-4517-80F5-B157B953C9D7Q40960952-C1AE0327-CBD8-442F-9861-7E2E7BFD9F61Q40989787-8BD10817-7829-4A77-9A4D-BA31B638B59FQ40989818-D9B540C6-10D1-4D8C-A99C-B0103122387EQ41180111-FB219E19-0050-48FB-B991-9EB80BF2C88DQ42334110-58BA53C3-2220-4DEA-BFB9-130CD6785443Q45324716-9F683196-AA3E-4A95-9B7A-20A351A3008AQ45325971-C0250E1F-D9C9-458D-8093-11B26FAFF54BQ45341796-5F683DCE-4E0C-4667-94F7-F10524F9189AQ47274730-AA264BA4-DEC4-4760-848A-642894FDE84BQ47554076-9122C1D3-DC8A-45A2-9B1C-E769F1B57F7AQ50270442-393138FC-01D0-41E6-B97B-D764D0D9379EQ52661695-78235689-54E1-42B6-91D0-503A8F7E025AQ57169238-E051EFF7-BFC7-4F41-B092-28B25593272E
P2860
Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Achieving sustained virologic ...... c and quality of life benefits
@ast
Achieving sustained virologic ...... c and quality of life benefits
@en
Achieving sustained virologic ...... c and quality of life benefits
@nl
type
label
Achieving sustained virologic ...... c and quality of life benefits
@ast
Achieving sustained virologic ...... c and quality of life benefits
@en
Achieving sustained virologic ...... c and quality of life benefits
@nl
prefLabel
Achieving sustained virologic ...... c and quality of life benefits
@ast
Achieving sustained virologic ...... c and quality of life benefits
@en
Achieving sustained virologic ...... c and quality of life benefits
@nl
P2093
P2860
P1476
Achieving sustained virologic ...... c and quality of life benefits
@en
P2093
Jayne Smith-Palmer
Karin Cerri
William Valentine
P2860
P2888
P356
10.1186/S12879-015-0748-8
P577
2015-01-17T00:00:00Z
P5875
P6179
1045152342